Literature DB >> 20353944

Differential requirements of Hsp90 and DNA for the formation of estrogen receptor homodimers and heterodimers.

Emily Powell1, Yidan Wang, David J Shapiro, Wei Xu.   

Abstract

The two estrogen receptor (ER) subforms, ERalpha and ERbeta, are capable of forming DNA-binding homodimers and heterodimers. Although binding to DNA is thought to stabilize ER dimers, how ERalpha/alpha, ERbeta/beta, and ERalpha/beta dimerization is regulated by DNA and the chaperone protein Hsp90 is poorly understood. Using our highly optimized bioluminescence resonance energy transfer assays in conjunction with assays for transcriptional activation of ERs, we determined that DNA binding appears to play a minor role in the stabilization of ER dimers, especially in the case of ERbeta/beta homodimers. These findings suggest that ER dimers form before they associate with chromatin and that DNA binding plays a minor role in stabilizing ER dimers. Additionally, although Hsp90 is essential for the proper dimerization of ERalpha/alpha and ERalpha/beta, it is not required for the proper dimerization of ERbeta/beta. Despite this, Hsp90 is critical for the estrogen-dependent transcriptional activity of the ERbeta/beta homodimer. Thus, Hsp90 is implicated as an important regulator of distinct aspects of ERalpha and ERbeta action.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353944      PMCID: PMC2871481          DOI: 10.1074/jbc.M110.104356

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins.

Authors:  Y Xu; D W Piston; C H Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

2.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

Authors:  S R Stauffer; C J Coletta; R Tedesco; G Nishiguchi; K Carlson; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

Review 3.  Clinical significance of estrogen receptor beta in breast cancer.

Authors:  Shigehira Saji; Makiko Hirose; Masakazu Toi
Journal:  Cancer Chemother Pharmacol       Date:  2005-11       Impact factor: 3.333

4.  Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.

Authors:  Angélique Gougelet; Céline Bouclier; Véronique Marsaud; Sébastien Maillard; Stefan O Mueller; Kenneth S Korach; Jack-Michel Renoir
Journal:  J Steroid Biochem Mol Biol       Date:  2005-02-23       Impact factor: 4.292

5.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.

Authors:  G B Tremblay; A Tremblay; N G Copeland; D J Gilbert; N A Jenkins; F Labrie; V Giguère
Journal:  Mol Endocrinol       Date:  1997-03

6.  Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.

Authors:  Merrill J Egorin; Theodore F Lagattuta; Deborah R Hamburger; Joseph M Covey; Kevin D White; Steven M Musser; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2002-01       Impact factor: 3.333

7.  Discrimination of DNA response elements for thyroid hormone and estrogen is dependent on dimerization of receptor DNA binding domains.

Authors:  M A Hirst; L Hinck; M Danielsen; G M Ringold
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 8.  Hsp90: an emerging target for breast cancer therapy.

Authors:  Jason Beliakoff; Luke Whitesell
Journal:  Anticancer Drugs       Date:  2004-08       Impact factor: 2.248

9.  A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.

Authors:  Chengjian Mao; Nicole M Patterson; Milu T Cherian; Irene O Aninye; Chen Zhang; Jamie Bonéy Montoya; Jingwei Cheng; Karson S Putt; Paul J Hergenrother; Elizabeth M Wilson; Ann M Nardulli; Steven K Nordeen; David J Shapiro
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

10.  Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta.

Authors:  J Sun; M J Meyers; B E Fink; R Rajendran; J A Katzenellenbogen; B S Katzenellenbogen
Journal:  Endocrinology       Date:  1999-02       Impact factor: 4.736

View more
  15 in total

Review 1.  Small molecule inhibitors as probes for estrogen and androgen receptor action.

Authors:  David J Shapiro; Chengjian Mao; Milu T Cherian
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

2.  A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.

Authors:  Nicole M Kretzer; Milu T Cherian; Chengjian Mao; Irene O Aninye; Philip D Reynolds; Rachel Schiff; Paul J Hergenrother; Steven K Nordeen; Elizabeth M Wilson; David J Shapiro
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

Review 3.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

4.  Identification and characterization of a novel estrogenic ligand actinopolymorphol A.

Authors:  Emily Powell; Sheng-Xiong Huang; Yong Xu; Scott R Rajski; Yidan Wang; Noel Peters; Song Guo; H Eric Xu; F Michael Hoffmann; Ben Shen; Wei Xu
Journal:  Biochem Pharmacol       Date:  2010-06-25       Impact factor: 5.858

5.  Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM.

Authors:  Amit K Maiti; Xana Kim-Howard; Prasenjeet Motghare; Vandana Pradhan; Kek Heng Chua; Celi Sun; María Teresa Arango-Guerrero; Kanjaksha Ghosh; Timothy B Niewold; John B Harley; Juan-Manual Anaya; Loren L Looger; Swapan K Nath
Journal:  Hum Mol Genet       Date:  2014-03-07       Impact factor: 6.150

Review 6.  Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?

Authors:  Karin Beelen; Wilbert Zwart; Sabine C Linn
Journal:  Nat Rev Clin Oncol       Date:  2012-07-24       Impact factor: 66.675

7.  Δ(9)-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ).

Authors:  Shuso Takeda; Kazutaka Yoshida; Hajime Nishimura; Mari Harada; Shunsuke Okajima; Hiroko Miyoshi; Yoshiko Okamoto; Toshiaki Amamoto; Kazuhito Watanabe; Curtis J Omiecinski; Hironori Aramaki
Journal:  Chem Res Toxicol       Date:  2013-06-11       Impact factor: 3.739

8.  Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.

Authors:  Ingrid J De Vries-van Leeuwen; Daniel da Costa Pereira; Koen D Flach; Sander R Piersma; Christian Haase; David Bier; Zeliha Yalcin; Rob Michalides; K Anton Feenstra; Connie R Jiménez; Tom F A de Greef; Luc Brunsveld; Christian Ottmann; Wilbert Zwart; Albertus H de Boer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-15       Impact factor: 11.205

9.  Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G.

Authors:  Zibo Zhao; Lu Wang; Taryn James; Youngeun Jung; Ikyon Kim; Renxiang Tan; F Michael Hoffmann; Wei Xu
Journal:  Chem Biol       Date:  2015-12-03

10.  Targeted genome-wide methylation and gene expression analyses reveal signaling pathways involved in ovarian dysfunction after developmental EDC exposure in rats.

Authors:  Aparna Mahakali Zama; Mehmet Uzumcu
Journal:  Biol Reprod       Date:  2013-02-28       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.